Cita APA (7a ed.)
Ravani, L. V., Bagheri, Z., Brufsky, A. M., Michellon, I., O'Regan, R., Lustberg, M., . . . Wander, S. A. (2025). Comparative efficacy of first- versus second-line CDK4/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer. Breast Cancer Research, 27(1), 1-14.
Cita Chicago Style (17a ed.)
Ravani, Lis Victoria, Zahra Bagheri, Adam M. Brufsky, Isabella Michellon, Ruth O'Regan, Maryam Lustberg, Hyo Han, Ming Wang, y Seth A. Wander. "Comparative Efficacy of First- Versus Second-line CDK4/6 Inhibition in Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer." Breast Cancer Research 27, no. 1 (2025): 1-14.
Cita MLA (9a ed.)
Ravani, Lis Victoria, et al. "Comparative Efficacy of First- Versus Second-line CDK4/6 Inhibition in Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer." Breast Cancer Research, vol. 27, no. 1, 2025, pp. 1-14.
Precaución: Estas citas no son 100% exactas.